Form 4: Entrada Therapeutics' President & COO, Nathan Dowden, Executes Stock Sale Under 10b5-1 Plan

Nathan Dowden, President & COO of Entrada Therapeutics, sold 1,826 shares of common stock at a weighted average price of $12.3213, executed under a pre-arranged 10b5-1 trading plan.

Summary

• On March 6, 2024, Nathan J Dowden, President & COO of Entrada Therapeutics, Inc. sold 1,826 shares of common stock.
• The sale was executed at a weighted average price of $12.3213 per share.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 20, 2023.
• Following the transaction, Dowden directly owns 137,204 shares of Entrada Therapeutics, Inc.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to an insider stock sale under a pre-arranged trading plan, which is neither particularly positive nor negative.

Industry Context

Sales by company insiders are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares over a period of time without being accused of trading on non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under 10b5-1 plans are generally viewed as less informative than discretionary trades.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the small volume of shares sold.

Key Dates